Poland· PL-100466458
Diklofenak Viatris
A diclofenac product containing diclofenacum epolaminum, registered in Poland by Cooper Consumer Health B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Diclofenac is registered in 14 of 19 countries.
Countries holding a registration under ATC M02AA15 (diclofenac), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Diclofenac · ATC M02AA15
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of diclofenac costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Diclofenac · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.43
The record
At a glance
URPL (Poland)- Active substance
- Diclofenacum epolaminum
- Manufacturer
- Cooper Consumer Health B.V.
- Country
- Poland (PL)
- ATC code
- M02AA15
- ATC class
- Diclofenac
- Defined daily dose
- 0.1 g, T
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05901797711153
- gtin05901797711146
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
131 interactions on record for diclofenac.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Diclofenac · interactions on record
131 records
- 9 severe
- 122 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M02AA15
Diclofenac, as other registers publish it.
- PolandAdarostinMilapharm Sp. z o.o.
- NetherlandsAlbert Heijn Diclofenac 1%, gelHealthypharm B.V.
- United StatesAleve Arthritis Pain GelBayer HealthCare LLC
- CzechiaALMIRALMedochemie Ltd., Limassol
- CzechiaALMIRALMedochemie Ltd., Limassol
- CzechiaALMIRALMedochemie Ltd., Limassol
- CzechiaALMIRALMedochemie Ltd., Limassol
- CzechiaALMIRALMedochemie Ltd., Limassol
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f6e49e67-262e-45d4-8cea-5853d279b4e0 GET /v1/drugs/f6e49e67-262e-45d4-8cea-5853d279b4e0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Plaster leczniczy",
"source": "urpl",
"strength": "180 mg",
"packaging": "05901797711153 ¦ OTC ¦ 147751\n10 plastrów\n05901797711146 ¦ OTC ¦ 147752\n5 plastrów",
"substance": "Diclofenacum epolaminum 180 mg (co odpowiada 140 mg Diklofenaku sodowego)",
"common_name": "Diclofenacum epolaminum",
"pl_product_id": "100466458",
"pozwolenie_nr": "27498",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about diclofenac.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.